TransThera Sciences (Nanjing). Inc. 2617
HKEX · Hong Kong SAR China · Health Technology
HKD 10.72-0.22 (-2.01%)
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
TransThera Sciences' Yochanra® is the first drug independently developed in China to address the longstanding global challenge of acquired resistance to FGFR inhibitor therapy in patients with cholangiocarcinoma. On 6 August 2026, the National Medical Products Administration (the "NMPA") formally approved the drug for marketing. As a global frontrunner in this field, the product had previously been granted Fast Track Designation and Orphan Drug Designation by the U.S. Food and Drug Administratio
TransThera Sciences Nanjing, Inc. (the "TransThera") announced that the new drug application for Tinengotinib tablets has been accepted by the Center for Drug Evaluation ("CDE")of the National Medical Products Administration ("NMPA") of the PRC. It is intended for the treatment of adults with unresectable advanced or metastatic cholangiocarcinoma (CCA) who have received at least one prior systemic treatment and FGFR inhibitor treatment. Previously, Tinengotinib tablets have been included in the
TransThera Sciences (Nanjing) (SEHK:2617) has quietly slipped about 4% over the past week and 13% over the past month, even after a huge jump over the past 3 months. See our latest analysis for TransThera Sciences (Nanjing). Even with the recent pullback, the stock still boasts a huge 90 day share price return of over 200% and a striking year to date share price return above 700%. This suggests momentum is cooling but not broken as investors reassess future growth and risk. If TransThera’s...
TransThera Sciences Inc. ("TransThera") announced the publication of clinical results from a US-based Phase 2 trial evaluating tinengotinib in patients with Cholangiocarcinoma (CCA) on The Lancet Gastroenterology and Hepatology (Impact Factor: 38.6).
TransThera Sciences Nanjing, Inc. (the "TransThera") announced that Tinengotinib tablets have been included in the List of Products for Priority Review by the Center for Drug Evaluation ("CDE") of the National Medical Products Administration ("NMPA") of the PRC, with the proposed indication for the treatment of adults with unresectable advanced or metastatic cholangiocarcinoma (CCA) who have received at least one prior systemic treatment and FGFR inhibitor treatment. Previously, Tinengotinib has
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.